Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–134 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: paroxetine Clear all

Conditions: Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions: Ginkgo Biloba, Sex Therapy (genital focus); Drug · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Any FDA Approved Antidepressant; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Major Depressive Disorder
Interventions: amibegron (SR58611A); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions: Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 24
States / cities: Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more

Conditions: Anxiety Disorders
Interventions: No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Social Anxiety Disorder, Social Phobia, Alcohol Use Disorder, Alcohol Abuse, Alcohol Dependence
Interventions: Paroxetine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bipolar Disorder
Interventions: Lithium, Valproic acid; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Menlo Park, California • San Diego, California + 4 more

Conditions: Major Depressive Disorder
Interventions: EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo; Drug
Lead sponsor: Euthymics BioScience, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 43
States / cities: Arcadia, California • Beverly Hills, California • National City, California + 39 more

Conditions: Healthy Volunteers
Interventions: Period 1, Period 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: PTSD
Interventions: Paroxetine CR; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

Effects of Treatment on Decision-making in Major Depression

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence